| Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents M Simeoni, P Magni, C Cammia, G De Nicolao, V Croci, E Pesenti, ... Cancer research 64 (3), 1094-1101, 2004 | 580 | 2004 |
| Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors R Bahleda, A Italiano, C Hierro, A Mita, A Cervantes, N Chan, M Awad, ... Clinical Cancer Research 25 (16), 4888-4897, 2019 | 225 | 2019 |
| Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor P Dostert, MS Benedetti, I Poggesi European Neuropsychopharmacology 7 (1), S23-S35, 1997 | 181 | 1997 |
| Physiologically based pharmacokinetics (PBPK) P Espié, D Tytgat, ML Sargentini-Maier, I Poggesi, JB Watelet Drug metabolism reviews 41 (3), 391-407, 2009 | 152 | 2009 |
| Drug metabolism and pharmacokinetics MS Benedetti, R Whomsley, I Poggesi, W Cawello, FX Mathy, ML Delporte, ... Drug metabolism reviews 41 (3), 344-390, 2009 | 151 | 2009 |
| Computational models for identifying potential P-glycoprotein substrates and inhibitors P Crivori, B Reinach, D Pezzetta, I Poggesi Molecular pharmaceutics 3 (1), 33-44, 2006 | 149 | 2006 |
| Predicting the active doses in humans from animal studies: a novel approach in oncology M Rocchetti, M Simeoni, E Pesenti, G De Nicolao, I Poggesi European journal of cancer 43 (12), 1862-1868, 2007 | 113 | 2007 |
| A mathematical model to study the effects of drugs administration on tumor growth dynamics P Magni, M Simeoni, I Poggesi, M Rocchetti, G De Nicolao Mathematical biosciences 200 (2), 127-151, 2006 | 107 | 2006 |
| Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs P Crivori, I Poggesi European journal of medicinal chemistry 41 (7), 795-808, 2006 | 98 | 2006 |
| Child–Pugh Classification: Time to Abandon? B Kok, JG Abraldes Seminars in liver disease 39 (01), 096-103, 2019 | 97 | 2019 |
| Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies E Marostica, J Sukbuntherng, D Loury, J De Jong, XW De Trixhe, ... Cancer chemotherapy and pharmacology 75, 111-121, 2015 | 87 | 2015 |
| First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery M Menichincheri, A Bargiotti, J Berthelsen, JA Bertrand, R Bossi, ... Journal of medicinal chemistry 52 (2), 293-307, 2009 | 85 | 2009 |
| Physiologically‐based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective T Heimbach, Y Chen, J Chen, V Dixit, N Parrott, SA Peters, I Poggesi, ... Clinical Pharmacology & Therapeutics 110 (2), 297-310, 2021 | 83 | 2021 |
| Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding DMF Edwards, C Pellizzoni, HP Breuel, A Berardi, MG Castelli, E Frigerio, ... Biopharmaceutics & drug disposition 16 (6), 443-460, 1995 | 78 | 1995 |
| Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate–treated castration-resistant prostate cancer patients XS Xu, CJ Ryan, K Stuyckens, MR Smith, F Saad, TW Griffin, YC Park, ... Clinical Cancer Research 21 (14), 3170-3177, 2015 | 75 | 2015 |
| Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates P Crivori, I Zamora, B Speed, C Orrenius, I Poggesi Journal of computer-aided molecular design 18, 155-166, 2004 | 68 | 2004 |
| Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics JC Fleishaker, M Mucci, C Pellizzoni, I Poggesi Biopharmaceutics & drug disposition 20 (1), 53-57, 1999 | 67 | 1999 |
| Low environmental radiation background impairs biological defence of the yeast Saccharomyces cerevisiae to chemical radiomimetic agents L Satta, G Augusti-Tocco, R Ceccarelli, A Esposito, M Fiore, P Paggi, ... Mutation Research Letters 347 (3-4), 129-133, 1995 | 63 | 1995 |
| Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer K Stuyckens, F Saad, XS Xu, CJ Ryan, MR Smith, TW Griffin, MK Yu, ... Clinical pharmacokinetics 53, 1149-1160, 2014 | 55 | 2014 |
| A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation M Valle, E Di Salle, MG Jannuzzo, I Poggesi, M Rocchetti, R Spinelli, ... British journal of clinical pharmacology 59 (3), 355-364, 2005 | 53 | 2005 |
